Distinct High-Profile Methylated Genes in Colorectal Cancer

Pooneh Mokarram, Krishan Kumar, Hassan Brim, Fakhreddin Naghibalhossaini, Mehdi Saberi-firoozi, Mehdi Nouraie, Robert Green, Ed Lee, Duane T. Smoot, Hassan Ashktorab

Department of Internal Medicine and Gastroenterology Research Center, Shiraz, Iran University of Medical Sciences, Tehran, Iran, 2 Department of Medicine and Cancer Center, Howard University, College of Medicine, Washington, D.C., United States of America, 3 Department of Pathology, Howard University, College of Medicine, Washington, D.C., United States of America

Abstract

**Background:** Mutations and promoters’ methylation of a set of candidate cancer genes (CAN genes) are associated with progression of colorectal cancer (CRC). We hypothesized that these genes’ promoters are inactivated through epigenetic silencing and may show a different profile in high-risk populations. We investigated the status of CAN gene methylation and CHD5 protein expression in African American CRC tissue microarrays (TMA) using immunohistochemical staining.

**Methodology/Principal Findings:** The promoter methylation status of the CAN genes was studied by methylation-specific PCR (MSP) in 51 Iranians (a white population) and 51 African Americans (AA). Microsatellite instability (MSI) was analyzed as well. The differential frequency of methylation for each gene was tested by chi-square analysis between the two groups based on matched age and sex. CHD5 protein expression was evaluated in moderate to well differentiated and poorly differentiated carcinomas compared to matched normal tissue using TMA. In addition, the correlation between these epigenetic biomarkers and various clinicopathological factors, including, age, location, and stage of the disease were analyzed. Seventy-seven and 34% of tumors were distal in Iranian and African American patients, respectively. In both populations, the percentage of methylation was >65% for SYNE1, MMP2, APC2, GPNM8, EVL, PTPRD, and STARD8, whereas methylation was <50% for LGR6, RET, CD109, and RNF. The difference in methylation between the two populations was statistically significant for CHD5, ICAM5 and GPNM8. Thirty-one percent AA tumors showed MSI-H, compared to 28% in Iranians.

**Conclusions/Significance:** A significantly higher methylation rate was found for GPNM8, ICAM5, and CHD5 genes in AA patients compared to Iranians. These genes might play a role in the high incidence and aggressiveness of CRC in the AA population. The hypermethylation of the CAN genes can be considered as a marker of colon carcinogenesis.

Introduction

Colon cancer (CRC) is remains the most prevalent gastrointestinal cancer in the United States [1]. The incidence and mortality rate of CRC are higher in AA [2,3]. A significant increase in CRC incidence with a predominant distal localization has also been reported in Iran over the last decade [4,5].

One of the CRC pathways involves transcriptional silencing by hypermethylation of CpG islands, which is referred to as the methylator phenotype (CIMP) [6] that mostly targets promoter regions of tumor suppressor genes (e.g., p16 and hMLH1 genes) [7,8,9]. It has recently been shown that genetic and epigenetic alterations of some candidate cancer genes (CAN genes) including SYNE1, MMP2, GPNM8, APC2, EVL, PTPRD, CD109, LGR6, STARD8, CD109, ICAM5, CHD5, RNF, and RET, are important in the progression of CRC [10,11].

The functional characterization of these genes with regards to tumor progression has not been clarified completely. These genes could be divided into 5 classes: (1) tumor suppressors, including adenomatous polyposis coli tumor suppressor homolog 2 (APC2) and protein-tyrosine phosphatase receptor type-delta (PTPRD); (2) genes that encode receptors, including rearranged during transfection proto-oncogene (RET), leucine-rich-repeat-containing G protein coupled receptor 6 (LGR6) and Ena/VASP like protein (EVL); (3) genes known to be involved in protein–protein and protein–DNA interactions, including STAR-related lipid transfer (START) domain-containing 8 (STARD8), ring finger protein (RFN182), CD109 antigen (CD109), glycoprotein NMB (GPNM8); (4) genes involved in metastasis and tumor growth, including intercellular adhesion molecule 5 (ICAM5), matrix metalloproteinase 2 (MMP2), and synaptic nuclear envelope protein 1 (SYNE1); and (5) genes whose expression is associated with changes in chromatin structure, such as chromodomain helicase DNA-binding protein 5 (CHD5).

These genes were chosen from many lists of potential cancer genes [11,12] because recent studies showed that in non-AA CRC,
their promoters are methylated and/or mutated [10]. This is, in fact, based on the comprehensive analysis by Sjoblom et al, where systematic sequencing of CRC tumors revealed the importance of these markers in CRC progression [11].

While most of these genes are novel, there is some functional data available in the literature. The receptors for glycoprotein hormones such as LGR6 are G protein-coupled 7-transmembrane receptors [13]. SYNE1 contains multiple spectrin repeats and a 60-amino acid C-terminal region homologous to the Drosophila protein Klarsicht. There are two mRNA isoforms, SYNE1A and SYNE1B, in skeletal and cardiac muscle [14,15].

The metastatic potential of tumor cells has been found to correlate with the activity of MMP2 enzyme [16] that are functionally active on the surface of angiogenic blood vessels [16]. CD109 is a GPI-linked cell surface antigen expressed by CD34+ acute myeloid leukemia cell lines, T-cell lines, activated T lymphoblasts, endothelial cells, and activated platelets [17]. The RING finger motif is a specialized zinc finger domain including a RING finger motif is a specialized zinc finger domain including a unique RING finger motif structure, through histones modification by acetylation and methylation [20]. It was noted that soluble ICAM5 level increased in the colony-stimulating factor of patients with acute encephalitis [21]. GPNMB is preferentially expressed in low-metastatic melanoma cell lines as glycoprotein [22]. In melanoma metastasis, there is an inverse relationship between the expression of GPNMB and cyclin or thymosin-beta-10, two other potential markers for the progression of cutaneous melanoma. Two-thirds of highly metastatic melanomas expressing recombinant GPNMB showed slower subcutaneous tumor growth, whereas one-third showed reduced potential for spontaneous metastasis in nude mice [22] or iris pigment dispersion in DBA/2J mice [23]. APC2 is involved in a series of molecular signals initiated by the binding of Wnt protein to a frizzled family receptor on the surface of the target cell and ending with a change in cell state [24,25]. APC2 protein interacts with a microtubule-associated protein, which effects beta-catenin-mediated growth signaling [24,25]. The co-expression of the EVL protein along with alpha-II spectrin reinforces cell-to-cell interaction. The methylation of the EVL gene in all poorly differentiated tumors suggests that it is a factor in cell invasiveness [26]. STARD8 was identified as a tumor suppressor gene that inhibits cancer growth [27]. It is located on chromosome Xq13 and encodes DCL-3 (related to Rho GTPase). Transfection of human breast and prostate cancer cells with a DCL-3 alpha expression vector inhibited cell proliferation, colony formation, and growth in soft agar [27].

In the present study, we analyzed samples from AA and Iranian patients for methylation of CAN genes’ promoters. We hypothesized that CAN genes were inactivated through epigenetic silencing and may show distinct methylation profiles in different populations.

Materials and Methods

Ethics Statement

This study was approved by Howard University Institutional Review Board, and written informed consent was obtained.

Study population, and tumor samples

A total of 102 CRC samples were used. Fifty-one sporadic CRC samples from Iranian patients, recruited at the hospitals of Shiraz University of Medical Sciences from 2003 to 2005 and 51 CRC samples from AA patients, recruited at Howard University Hospital, matched by sex, age (with ≤ 5 years) and stage, were included in this study. All samples were evaluated and subjected to histological diagnosis by expert pathologists. Tissues were collected (with approval from all above sites’ Institutional Review Boards and clinical data was obtained (including race, age, site of primary tumor, stage, and tumor differentiation). Family history of cancer was analyzed to exclude those pedigrees that met either the Amsterdam I or Amsterdam II criteria.

Methylation-specific PCR

The promoter methylation status of the CAN genes was determined as described previously [28,29,30]. The sequences of primers used for amplification of the promoter regions of each of the CAN genes are listed in Table 1. The MS-PCRs were performed as previously described (Table 1) [10]. The MSP primers were designed using a software developed at the Johns Hopkins University (www.mspprimer.org) [10] based on the sequences for which the accession numbers and corresponding function are given in Table 2. The PCR conditions were as follow: hotstart Taq polymerase (Qiagen) used with initial activation and denaturation 95°C × 15 min; 35 cycles [95°C × 45 sec; 60°C × 45 sec; 72°C × 1 min] followed by final extension 72°C × 10 min. In vitro methylated DNA and unmethylated lymphocytes DNA were used as positive and negative controls, respectively. The annealing temperature was 56°C for APC2 and CD109 [10], respectively, while it was 60°C for all other genes (Table 1).

DNA isolation and MSI analysis

Archived and fresh tumor blocks were cut into 5-μm sections on Superfrost slides (Fisher Scientific, Pittsburgh, PA). The tumor and normal areas were diagnosed by a pathologist using the H&E histological diagnosis by expert pathologists. Tissues were collected (with approval from all above sites’ Institutional Review Boards and clinical data was obtained (including race, age, site of primary tumor, stage, and tumor differentiation). Family history of cancer was analyzed to exclude those pedigrees that met either the Amsterdam I or Amsterdam II criteria.

DNA isolation and MSI analysis

Archived and fresh tumor blocks were cut into 5-μm sections on Superfrost slides (Fisher Scientific, Pittsburgh, PA). The tumor and normal areas were diagnosed by a pathologist using the H&E histological diagnosis by expert pathologists. Tissues were collected (with approval from all above sites’ Institutional Review Boards and clinical data was obtained (including race, age, site of primary tumor, stage, and tumor differentiation). Family history of cancer was analyzed to exclude those pedigrees that met either the Amsterdam I or Amsterdam II criteria.

DNA isolation and MSI analysis

Archived and fresh tumor blocks were cut into 5-μm sections on Superfrost slides (Fisher Scientific, Pittsburgh, PA). The tumor and normal areas were diagnosed by a pathologist using the H&E histological diagnosis by expert pathologists. Tissues were collected (with approval from all above sites’ Institutional Review Boards and clinical data was obtained (including race, age, site of primary tumor, stage, and tumor differentiation). Family history of cancer was analyzed to exclude those pedigrees that met either the Amsterdam I or Amsterdam II criteria.

DNA isolation and MSI analysis

Archived and fresh tumor blocks were cut into 5-μm sections on Superfrost slides (Fisher Scientific, Pittsburgh, PA). The tumor and normal areas were diagnosed by a pathologist using the H&E histological diagnosis by expert pathologists. Tissues were collected (with approval from all above sites’ Institutional Review Boards and clinical data was obtained (including race, age, site of primary tumor, stage, and tumor differentiation). Family history of cancer was analyzed to exclude those pedigrees that met either the Amsterdam I or Amsterdam II criteria.

DNA isolation and MSI analysis

Archived and fresh tumor blocks were cut into 5-μm sections on Superfrost slides (Fisher Scientific, Pittsburgh, PA). The tumor and normal areas were diagnosed by a pathologist using the H&E histological diagnosis by expert pathologists. Tissues were collected (with approval from all above sites’ Institutional Review Boards and clinical data was obtained (including race, age, site of primary tumor, stage, and tumor differentiation). Family history of cancer was analyzed to exclude those pedigrees that met either the Amsterdam I or Amsterdam II criteria.

DNA isolation and MSI analysis

Archived and fresh tumor blocks were cut into 5-μm sections on Superfrost slides (Fisher Scientific, Pittsburgh, PA). The tumor and normal areas were diagnosed by a pathologist using the H&E histological diagnosis by expert pathologists. Tissues were collected (with approval from all above sites’ Institutional Review Boards and clinical data was obtained (including race, age, site of primary tumor, stage, and tumor differentiation). Family history of cancer was analyzed to exclude those pedigrees that met either the Amsterdam I or Amsterdam II criteria.

DNA isolation and MSI analysis

Archived and fresh tumor blocks were cut into 5-μm sections on Superfrost slides (Fisher Scientific, Pittsburgh, PA). The tumor and normal areas were diagnosed by a pathologist using the H&E histological diagnosis by expert pathologists. Tissues were collected (with approval from all above sites’ Institutional Review Boards and clinical data was obtained (including race, age, site of primary tumor, stage, and tumor differentiation). Family history of cancer was analyzed to exclude those pedigrees that met either the Amsterdam I or Amsterdam II criteria.
Histopathological analysis

Independent pathologists evaluated specific histopathological characteristics. Grading of tumors was achieved by staining with Hematoxylin-Eosin (H&E). Tumors were classified as proximal or distal (to the splenic flexure). The TNM system of the International Union against cancer was used for tumor staging.

Statistical analysis

Age of patients was a continuous variable, while race, gender, location, differentiation, stage, MSI, and CAN genes methylation were categorical variables. The distribution of categorical variables were shown by frequency table, and for age by computing mean (SD). Associations between methylation of loci with age, race, gender, differentiation, MSI, stage and tumor location were evaluated using a chi square test. The age difference between two groups was tested by the Student’s t test. All analysis were performed using SPSS 15.0 software (Chicago, IL).

Results

Clinicopathological characteristics of patients

We analyzed 102 samples (38 females and 64 males) from Iranian and AA patients (Table 3). The mean age (SD) for carcinoma in AA was 61.5 (12) years and 60 (13) years in Iranians. There was no significant difference in sex or age between the two analyzed populations. A total of 57% and 24% of tumors were proximal in AA and Iranian patients, respectively. A higher incidence of distal tumors was present in Iranians in comparison to the AA patients (Table 3). The majority of tumors were at advanced stages with 57% at stage II in Iranians, and 52% at stage III+IV in AA (Table 3). The majority of tumors (85%) were found to be moderately differentiated in AA while Iranian tumors were mostly well differentiated (53%).

SYNE1 and RNF182 gene methylation profiles

The SYNE1 promoter was found to be methylated in all 102 analyzed samples (Table 3). The SYNE1 promoter was found to be methylated in all 102 analyzed samples (Table 3).
RNF182 gene promoter was unmethylated in all analyzed samples (Table 4). This finding will put in question its status as a candidate for methylation in colon cancer carcinogenesis.

**Table 2.** CAN genes, their functions and corresponding Accession number.

| Gene    | Gene Name                  | Gene Function                                                                 | References            | Accession Number |
|---------|----------------------------|-------------------------------------------------------------------------------|-----------------------|------------------|
| APC2    | Adenomatosis polyposis coli 2 | Wnt transduction pathway                                                      | [25,26]               | NM_005883.2      |
| CD109   | CD109 molecule              | Expressed in CD34+ acute myeloid leukemia and other blood cell lines           | [17]                  | NM_133493.2      |
| CHD5    | Chromodomain helicase DNA binding protein 5 | Intervenes in chromatin modification through histones acetylation and methylation | [21]                  | NM_015557.1      |
| EVL     | Enah/Vasp-like              | Strengthen cell-to-cell interaction                                           | [27]                  | NM_016337.2      |
| GPNMB   | Glycoprotein (transmembrane) nmb | Expressed in low metastatic melanomas cell lines                             | [23]                  | NM_001005340.1   |
| ICAM5   | Intercellular adhesion molecule 5, telencephalin | Highly expressed in the colony-stimulating factor of patients with acute encephalitis | [22]                  | NM_003259.2      |
| LGR6    | Leucin-rich repeat-containing G protein-coupled receptor 6 | Receptor for glycoproteins Hormones                                           | [13]                  | NM_021636.2      |
| MMP2    | Matric metallopeptidase 2   | Active on angiogenic blood vessels, metastasis                               | [16]                  | NM_004530.2      |
| PTPRD   | Protein tyrosin phosphatase, receptor-type, D | TSG, involved in a wide range of common human cancers                        | [51]                  | NM_130391.2      |
| RET     | Ret proto-oncogene          | Associated with multiple endocrine neoplasias type IIA and IIB               | [19]                  | NM_020975.4      |
| RNF182  | Ring finger protein 182     | Found to many transcriptional regulatory proteins                            | [18]                  | NM_152737.2      |
| STAR8   | START domain contain 8      | TSG, inhibits cancer growth                                                   | (27,52)               | NM_014725.2      |
| SYNE1   | Spectrin repeat containing, nuclear envelope 1 | Expressed in skeletal and cardiac muscles                                     | (14,15)               | NM_182961.1      |

doi:10.1371/journal.pone.0007012.t002

Gender and CAN gene methylation

Nine out of 13 genes showed gender-independent levels of methylation (Table 5). The RET gene displayed a higher level of methylation in males (45%) than in females (29%). This difference, however, was not found to be statistically significant. The APC2, PTPRD and STAR8 genes were found to have significantly different methylation profiles in the two genders, with APC2 being hypomethylated in males (98% vs. 90%); PTPRD and STAR8 were hypermethylated in females (90% vs. 67%) and (84% vs. 61%), respectively.

Age and CAN gene methylation

None of the 13 genes analyzed showed any age-dependent methylation profile, although ICAM5 and CD109 showed non-
statistically significant differences (Table 5). This finding is consistent with the way the genes were chosen and supports the idea that most of them are targeted by methylation in a carcinogenic process.

**Tumor location and CAN gene methylation**

Ten of the analyzed genes have similar methylation levels, regardless of the tumor location (Table 5). However, CD109, LGR6, and ICAM5 displayed higher methylation levels in proximal tumors than in distal ones. Methylation frequency of CD109 was 43% in proximal tumors vs. 21% in distal tumors. These numbers for ICAM5 were 34% in proximal and 16% in distal tumors, respectively (p < 0.05). For the LGR6 gene, the difference (51% vs. 33%) was not statistically significant.

**Tumor differentiation and CAN gene methylation**

While 8 genes displayed different methylation profiles at different levels of differentiation, only two showed statistically significant differences (ICAM5 and MMP2). However, there was no correspondence with tumor progression toward poor differentiation (Table 5). Only the APC2 and EVL genes displayed higher methylation in the normal progression of a tumor from well to moderate to poor differentiation, with the APC2 gene showing 91%, 97%, and 100% and the EVL gene showing 75%, 77%, and 100%, respectively. These findings might underscore the role of these genes in the tumor differentiation process.

**Tumor stage and CAN gene methylation profile**

Eight genes showed different methylation profiles at different tumor stages, with the LGR6 and APC2 genes displaying statistically significant differences with higher methylation at stage 1 and lower methylation at advanced stages in the case of LGR6 and lower methylation at stage 1 and higher methylation at advanced stages in the case of APC2 (Table 5). The only gene that showed a higher methylation at more advanced tumor stages was CD109, which was methylated at a rate of 56%, 76%, and 86% at stages I, II and (III+IV), respectively.

**MSI and CAN gene methylation**

The MSI rate was 28% for Iranians and 31% for AA (Table 3), respectively. Twelve of the 13 tested genes showed no differences in methylation levels between MSI-H and non MSI-H tumors in both populations. An exception could be made for the PTPRD gene with a statistically significant association with MSI-H (P < 0.05) in both populations (Table 5). Therefore, there is a possibility that the methylation of PTPRD is linked to the MSI-H phenotype.

**Population to Population comparison**

The methylation profiles of at least 9 genes in the two analyzed populations was similar without significant differences (Table 4 and figure 1): APC2, SYNE1, EVL, MMP2, CD109, RNF182, PTPRD, STARD, and RET. For the LGR6 gene, there was a substantial difference, although statistically insignificant, in methylation levels with 31% vs. 49% in Iranians and AA, respectively. For three genes, namely GPNMB, CHD5, and ICAM5, there were statistically significant differences in the methylation level, with AA displaying higher methylation levels than Iranians, 100%, 78%, and 40% vs. 89%, 47%, and 7.5% for the three genes, respectively (Table 4). SYNE1 and REN were fully methylated and unmethylated, respectively for all samples tested.

**CHD5 expression by IHC, Differentiation and Tumor Stage**

Since one of our laboratory’s main focuses is to tackle the issue of the high incidence of CRC in AA and, based on the fact that CHD5 promoter is highly methylated in this population and seems to be involved in early stages of carcinogenesis as a chromatin modifier, we analyzed its expression by IHC to validate the methylation results. Among 59 CRC cases available for analysis, the number of subjects with stage I, II, III, and IV were 14 (24.5%), 20 (35.1%), 21 (36.8), 2 (3.5%), and 2 (missing) respectively. In general, there were no statistically significant differences for age, sex, anatomic location, CHD5 expression with tumor stage (data not shown). Expression of CHD5 (Fig. 2G) was lost in 80% of AA patients and 52% in Iranian patients with stage

| Table 5. Distribution of the CAN genes methylation (%) by demographic and clinical characteristics of CRC in the AA and Iranian populations. |
| --- |
| **N = 102** | APC2 | GPNMB | EVL | MMP2 | CD109 | CHD5 | LGR6 | PTPRD | STARD | RET | ICAM5 |
| **Gender** |  |  |  |  |  |  |  |  |  |  |  |
| Male | 98* | 95 | 72 | 97 | 34 | 64 | 37 | 67** | 61* | 45 | 23 |
| Female | 90* | 92 | 81 | 97 | 24 | 60 | 42 | 90** | 84* | 29 | 24 |
| **Age** |  |  |  |  |  |  |  |  |  |  |  |
| <60 | 96 | 94 | 74 | 98 | 25 | 66 | 38 | 77 | 72 | 47 | 19 |
| ≥60 | 94 | 94 | 77 | 96 | 37 | 58 | 43 | 71 | 67 | 31 | 29 |
| **Location** |  |  |  |  |  |  |  |  |  |  |  |
| Distal | 95 | 93 | 74 | 98 | 21* | 57 | 33 | 72 | 69 | 39 | 16* |
| Proximal | 95 | 95 | 78 | 95 | 43* | 71 | 51 | 78 | 71 | 39 | 34* |
| **Differentiation** |  |  |  |  |  |  |  |  |  |  |  |
| Poor | 100 | 67 | 100 | 75* | 0 | 67 | 50 | 75 | 50 | 0 | 0** |
| Moderate | 97 | 97 | 77 | 98* | 31 | 66 | 38 | 72 | 69 | 39 | 34** |
| Well | 91 | 91 | 75 | 97* | 34 | 50 | 38 | 78 | 69 | 38 | 6** |
| **Stage** |  |  |  |  |  |  |  |  |  |  |  |
| 0,1 | 82* | 94 | 65 | 94 | 24 | 82 | 71** | 77 | 71 | 35 | 24 |
| 2 | 98* | 93 | 78 | 100 | 27 | 49 | 24** | 71 | 66 | 42 | 15 |
| 3,4 | 97* | 94 | 75 | 95 | 35 | 61 | 43** | 78 | 70 | 35 | 32 |
| **MSI** |  |  |  |  |  |  |  |  |  |  |  |
| High | 100 | 91 | 83 | 100 | 33 | 61 | 38 | 92* | 75 | 42 | 29 |
| Non-MSI | 94 | 95 | 72 | 96 | 30 | 62 | 40 | 70* | 68 | 38 | 21 |

SYNE1 and REN were fully methylated and unmethylated, respectively for all samples tested.
p < 0.05 **p < 0.01.
doi:10.1371/journal.pone.0007012.t005
II and III disease, respectively. However, the difference was not statistically significant. The loss of CHD5 expression was consistent with CHD5 methylation in CRC. The cytoplasmic expression of CHD5 was present in normal colon epithelial cells (Fig. 2A) compared to the negative control without the primary antibody (Fig. 2B), indicating the specificity of the antibody.

**Discussion**

Epigenetic analysis of tumor cells plays a major role in the understanding of carcinogenic processes and targeted therapies [7]. Sjoblom et al. have sequenced thousands of genes in 11 primary breast and colon tumors and concluded that every single tumor has an average of 14 genetic alterations [11]. A subsequent epigenetic and mutation study [10] led to the identification of silenced promoters, 13 of which correspond to the CAN genes analyzed in this study [11]. We decided to investigate the impact of these 13 genes in CRC using two different sample populations. Our choice of the 13 genes was based on the fact that they were established from a high throughput technology and a comprehensive study involving both cell lines and clinical white colon samples that were validated using DNA from normal and cancer tissue [10,11,33]. Here, we analyzed the methylation profile of these 13 genes in AA and Iranian CRC, the MSI status and the expression by IHC of CHD5, a gene suspected to be involved in early carcinogenic processes.

Most of the analyzed genes were highly methylated with different levels of methylation from one gene to another and one expression of CHD5 was present in normal colon epithelial cells (Fig. 2A) compared to the negative control without the primary antibody (Fig. 2B), indicating the specificity of the antibody.

**Figure 1.** Graphical presentation of methylation frequencies (%) of the CAN genes in the studied populations. doi:10.1371/journal.pone.0007012.g001

**Figure 2.** Immunohistochemical staining of CHD5 in human tissue microarray (A, B, C). (A) Positive CHD5 staining evident in all of the normal glands in biopsy specimens from normal colon biopsies (B) in normal patients lack of brown color indicates absence of cytoplasmic staining for CHD5 in absence of primary antibody, (C) in CRC patients (>52%) of the cases showed absence of cytoplasmic staining for CHD5 in the malignant epithelial cells. doi:10.1371/journal.pone.0007012.g002
population to the other. SYNE1, a synaptic nuclear envelope encoding protein, was methylated in all analyzed samples while the RNF182 promoter, encoding a ring finger protein, was methylated in none. No known function for the RNF182 gene is available to date. SYNE1 protein was shown to be involved in the process of cytokinesis [34] where this protein and KIF3B protein facilitate the accumulation of membrane vesicles at the spindle midbody.

The methylation profile of the analyzed genes was shown to be independent of age (Table 5). While there is a general methylating process that is age dependent and is not gene/disease specific, the results obtained with the analyzed genes reflect the relevance of these genes in the process of carcinogenic-dependent methylation. These findings are strengthened by the fact that many of the patients involved in this study, especially Iranians, are relatively young (40 years).

At least four genes showed a level of methylation that depends on the patient gender. A higher level of methylation in male patients was found for APC2 and RET, while a higher level of methylation in female patients was displayed for PTPRD and STARD8 genes (Table 5). At least four genes (CD109, CHD5, LGR6, and ICAM5) displayed a different level of methylation, depending on the tumor location. These genes showed a lower level of methylation in the distal colon. This finding is in agreement with the presence of a descending methylation gradient from the proximal to the distal colon. A higher level of methylation from well to poorly differentiated tumors was observed only for the EVL gene promoter. Bournier et al. have shown that the co-expression of the EVL protein along with alpha-II spectrin reinforces the cell-to-cell interaction [26]. The methylation of the EVL gene in all poorly differentiated tumors and more than 75% of well and moderately differentiated ones increases their invasiveness. This finding is strengthened by the fact that this gene methylation increases also in advanced stage tumors where only 65% of stage-I tumors were methylated compared to 75% at stage IV. An apparently stage-dependent methylation was observed for LGR6, which encodes a Leucine-rich repeat-containing G-protein-coupled receptor, and is thus involved in cell proliferation [13]. However, this decrease in methylation status from stage I to stage IV (71% to 43%) cannot be explained in light of this gene function as a proliferation promoter. APC2 stage-dependent methylation from stage I to stage IV (82% to 97%) was also observed and this may be consistent with the tumor suppressor activity of APC2 gene in CRC and its link to the Wnt pathway.

The multivariate analysis for the effect of confounders (site, differentiation and stage) is different among the two populations (Table 5). To be confounders these variables need to be correlated with methylation, too. As shown in table 5, ICAM5 is correlated with differentiation and site while GPNMB and CHD5 are not related to any of these variables. Based on these findings, site and differentiation may have a confounder role for ICAM5. To be consistent and inclusive in statistical analysis, we developed three logistic regression models using forward selection with each gene consistent and inclusive in statistical analysis, we developed three logistic regression models using forward selection with each gene
both whole-genome methylation and/or chromatin modification inhibitors followed by differential microarray expression studies.

Acknowledgments

We would like to thank Mohammad Daremipouran for running some of the methylation assay.

References

1. Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2: 533–543.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43–65.
3. Carey RM, Jiang X, Murray CJ, Edwards B, Forman D, et al. (2007) Cancer incidence, mortality, and prevalence in the United States: The Surveillance, Epidemiology, and End Results (SEER) Programme of the National Cancer Institute, 1998–2002. Natl Acad Sci U S A 97: 710–715.
4. Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50: 113–130.
5. Herman JG, Younger J, Wilson MT, Torrance D, Halden CR, et al. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95: 6707–6711.
6. Bournier O, Kroviarski Y, Rotter B, Nicolas G, Lecomte MC, et al. (2006) Mutations in the CDKN2A/c-Myc and CDKN2B/p15 genes in colorectal cancer. Int J Cancer 114: 4485–4499.
7. overall. 2007. National Cancer Institute. Cancer Incidence in Five Continents, Volume 8. IARC Press, Lyon.
8. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, et al. (2007) The CpG island methylator phenotype in colorectal cancer. Int J Cancer 119: 2272–2278.
9. Ashktorab H, Smoot DT, Caruthers JM, Rahmanian M, Kimbrell K, et al. (2001) High incidence of microsatellite instability in colorectal cancer from African Americans. Clin Cancer Res 9: 1112–1117.
10. Ashktorab H, Smoot DT, Farzanmehr H, Fidelia-Lambert M, Momen B, et al. (2005) Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. Int J Cancer 116: 914–919.
11. Sjoblom T, Jones S, Wood LD, Saito Y, Parsons DW, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274.
12. Kuan CT, Wakiya K, Dowell JM, Herndon JE 2nd, Reardon DA, et al. (2006) Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 12: 1970–1982.
13. Satia JA, Keku T, Galanko JA, Martin C, Doctolero RT, et al. (2005) Diet, lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colorectal cancer. Int J Cancer 116: 914–919.
14. Goodman JE, Bowsmen ED, Channock SJ, Alberg AJ, Harris CC (2004) Arachidonic lipooxygenase (Alox) and cytochrome Oxidase (Cox) polymorphisms and colon cancer risk. Carcinogenesis 25: 2434–2438.
15. King BL, Carcangiu ML, Carter D, Kiechle M, Pletcher J, et al. (1995) Microsatellite instability in ovarian neoplasms. Br J Cancer 72: 376–382.
16. Klaunzer F, Cordero-Castillo J, Juretic-Chakraborty K, Statter F, Bernkop-Scheener R, et al. (2007) Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 120: 656–663.
17. Goodman JE, Bowsmen ED, Channock SJ, Alberg AJ, Harris CC (2004) Arachidonic lipooxygenase (Alox) and cytochrome Oxidase (Cox) polymorphisms and colon cancer risk. Carcinogenesis 25: 2434–2438.
18. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, et al. (2007) The CpG island methylator phenotype in colorectal cancer. Int J Cancer 119: 2272–2278.
19. Sjoblom T, Jones S, Wood LD, Saito Y, Parsons DW, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274.
20. Kuan CT, Wakiya K, Dowell JM, Herndon JE 2nd, Reardon DA, et al. (2006) Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 12: 1970–1982.
21. Satia JA, Keku T, Galanko JA, Martin C, Doctolero RT, et al. (2005) Diet, lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colorectal cancer. Int J Cancer 116: 914–919.
22. Klaunzer F, Cordero-Castillo J, Juretic-Chakraborty K, Statter F, Bernkop-Scheener R, et al. (2007) Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 120: 656–663.
23. Goodman JE, Bowsmen ED, Channock SJ, Alberg AJ, Harris CC (2004) Arachidonic lipooxygenase (Alox) and cytochrome Oxidase (Cox) polymorphisms and colon cancer risk. Carcinogenesis 25: 2434–2438.
24. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, et al. (2007) The CpG island methylator phenotype in colorectal cancer. Int J Cancer 119: 2272–2278.
25. Sjoblom T, Jones S, Wood LD, Saito Y, Parsons DW, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274.
26. Klaunzer F, Cordero-Castillo J, Juretic-Chakraborty K, Statter F, Bernkop-Scheener R, et al. (2007) Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 120: 656–663.
27. Goodman JE, Bowsmen ED, Channock SJ, Alberg AJ, Harris CC (2004) Arachidonic lipooxygenase (Alox) and cytochrome Oxidase (Cox) polymorphisms and colon cancer risk. Carcinogenesis 25: 2434–2438.
28. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, et al. (2007) The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 132: 127–138.
29. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, et al. (2007) Integrated genetic and epigenetic analysis identifies three distinct subclasses of colon cancer. Proc Natl Acad Sci U S A 104: 18654–18659.

Author Contributions

Performed the experiments: PM KK HB. Analyzed the data: MN. Contributed reagents/materials/analysis tools: FN MSf RG ELL DTS. Wrote the paper: HA.
51. Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, et al. (2008) Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res 68: 10300–10306.

52. Kawai K, Kiyota M, Seike J, Deki Y, Yagisawa H (2007) START-GAP3/DLC3 is a GAP for RhoA and Cdc42 and is localized in focal adhesions regulating cell morphology. Biochem Biophys Res Commun 364: 783–789.